Insight Molecular Diagnostics Inc expected to post a loss of 23 cents a share - Earnings Preview

Insight Molecular Diagnostics

08/08/2025 22:35

Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 for the period ending June 30 2025

The Nashville Tennessee-based  company is expected to report a 180.8% increase in revenue to $292 thousand from $104 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Insight Molecular Diagnostics Inc is for a loss of 23 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Insight Molecular Diagnostics Inc is $4.25, about 38.2% above its last closing price of $2.63

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.24
-0.24
-0.26
Missed
-9.9
Dec. 31 2025
-0.44
-0.43
-1.93
Missed
-351.6
Sep. 30 2024
-0.44
-0.44
-0.98
Missed
-124.8​
Jun. 30 2024
-0.55
-0.56
-0.36
Beat
35.6
​​Mar. 31 2024
-0.65
-0.67
-1.13
Missed
-69.1
Dec. 31 2023
-1.14
-2.12
Missed
-86.5​
Sep. 30 2023
-1.00
-1.01
-0.81
Beat
19.6
Jun. 30 2023
-0.68
-1.30
-1.07
Beat
17.7

This summary was machine generated August 8 at 21:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)